Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dopaminergic therapy with rotigotine for behavioral variant frontotemporal dementia
2019-002997-30Phase 2Completed
- Sponsor
- Fondazione Santa Lucia IRCCS
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rotigotine in frontotemporal dementia (FTD), sponsored by Fondazione Santa Lucia IRCCS. Primary endpoint: Change from baseline to Week 24 in Frontal Assessment Battery. Started Oct 2021; status: completed.
02
Drugs
rotigotine
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on 2019-002997-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002997-30.